In short
This article discusses clinical trials investigating [18F]MC225, a radiotracer used in PET imaging to measure P-glycoprotein (P-gp) function in the brain. Current trials are evaluating [18F]MC225 in patients with treatment-resistant depression and neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, and mild cognitive impairment. These Phase 2 studies aim to assess how P-gp activity differs in these conditions.
Key points
- Clinical trials are investigating [18F]MC225, a radiotracer used in PET imaging, to measure P-glycoprotein function in the brain. Two Phase 2 trials are currently authorized, enrolling a total of 74 participants. One trial focuses on treatment-resistant depression, comparing P-gp activity between patients who respond to treatment and those who do not. The other trial evaluates P-gp function in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and mild cognitive impairment. Both studies use PET/CT imaging after intravenous administration of [18F]MC225 to assess regional brain uptake and distribution patterns. These trials aim to better understand the role of P-glycoprotein in these neurological and psychiatric conditions.
Overview of [18F]MC225 Clinical Research
[18F]MC225 is a radiotracer being investigated in clinical trials for its ability to measure P-glycoprotein (P-gp) function in the brain using PET/CT imaging. Currently, two Phase 2 clinical trials have been authorized to study this imaging agent in different patient populations.
The chemical name of [18F]MC225 is 5-(1-(2-[18F]fluoroethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen. This compound is labeled with fluorine-18, a radioactive isotope that allows it to be detected by PET scanners.
These clinical trials represent important research efforts to understand how P-glycoprotein activity may be altered in various brain disorders. The trials are investigating both psychiatric conditions, specifically treatment-resistant depression, and neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and mild cognitive impairment.
Understanding P-glycoprotein Function
P-glycoprotein is a protein that functions as a transporter in cell membranes throughout the body, with particularly important roles at the blood-brain barrier. This barrier is a protective system that controls which substances can enter brain tissue from the bloodstream.
P-gp acts as an efflux pump, meaning it actively pumps certain substances out of cells and prevents them from entering the brain. This mechanism serves several important functions:
- Protection: P-gp helps protect the brain from potentially toxic compounds by preventing their entry into brain tissue
- Drug transport: P-gp can affect how medications reach the brain, which may influence treatment effectiveness
- Disease involvement: Changes in P-gp function have been linked to various neurological and psychiatric conditions
Understanding P-gp activity in different disease states may help explain why some patients respond to treatments while others do not, and could lead to better therapeutic approaches.
Clinical Trial in Treatment-Resistant Depression
The first authorized trial (2023-508303-20-01) is investigating the role of P-glycoprotein in treatment-resistant depression (TRD). This Phase 2 interventional study plans to enroll 44 participants.
The primary aim of this study is to assess the involvement of P-gp in TRD by comparing P-gp activity between two groups of patients:
- Subjects with treatment-resistant depression: Patients whose depression has not responded adequately to standard antidepressant treatments
- Subjects with treatment-responsive depression (DRESP): Patients whose depression has responded well to antidepressant medications
The study uses [18F]MC225 PET/CT imaging to measure P-gp activity in the brain. The hypothesis behind this research is that differences in P-gp function may explain why some patients respond to antidepressant medications while others do not.
If P-gp is more active in patients with treatment-resistant depression, it might be pumping antidepressant medications out of the brain before they can have their therapeutic effect. This would represent an important mechanism of treatment resistance and could point to new therapeutic strategies.
Clinical Trial in Neurodegenerative Diseases
The second authorized trial (2024-518865-85-00) is evaluating [18F]MC225 to measure P-glycoprotein function in patients with neurodegenerative diseases. This Phase 2 study plans to enroll 30 participants.
The trial is investigating three related neurodegenerative conditions:
- Alzheimer's disease: A progressive brain disorder that causes memory loss and cognitive decline, characterized by the buildup of abnormal proteins in the brain
- Mild Cognitive Impairment (MCI): A condition involving noticeable decline in cognitive abilities that is greater than expected for age but not severe enough to interfere significantly with daily activities; MCI may progress to Alzheimer's disease
- Parkinson's disease: A progressive disorder affecting movement and coordination, caused by loss of nerve cells in specific brain regions
Changes in P-glycoprotein function have been observed in neurodegenerative diseases and may contribute to disease progression. P-gp alterations could affect the accumulation of toxic proteins in the brain or influence how medications used to treat these conditions reach their targets.
This trial aims to characterize P-gp function across these different neurodegenerative conditions, which may help researchers understand disease mechanisms and develop better treatments.
How [18F]MC225 is Administered
[18F]MC225 is administered as an intravenous injection, meaning it is injected directly into a vein. The dose used in the clinical trial for neurodegenerative diseases is 400 MBq (megabecquerel), which is a unit measuring radioactivity.
The administration process typically involves the following steps:
- Preparation: The radiotracer is prepared in a specialized facility and must be used within a short time frame due to the radioactive decay of fluorine-18
- Injection: The [18F]MC225 solution is injected intravenously, usually into an arm vein
- Distribution: After injection, the radiotracer circulates through the bloodstream and crosses into the brain
- Imaging: PET/CT scanning is performed to detect where the radiotracer accumulates in the brain
The amount of radiation exposure from [18F]MC225 is comparable to other diagnostic nuclear medicine procedures and is considered safe for research purposes when appropriate safety protocols are followed.
What the Trials are Measuring
Both clinical trials use specialized imaging measurements to assess P-glycoprotein function in the brain. These measurements provide quantitative data about how [18F]MC225 is distributed in brain tissue.
The trial in treatment-resistant depression is measuring P-gp activity by assessing [18F]MC225 standardized uptake value (SUV) and volume distribution (VD) in the whole brain. SUV is a measurement that indicates how much radiotracer has accumulated in brain tissue, while volume distribution describes how the tracer spreads throughout the brain.
The trial in neurodegenerative diseases is measuring regional PET tracer uptake and influx values of [18F]MC225. This approach examines specific brain regions rather than the whole brain, which may reveal regional differences in P-gp function that are relevant to different neurodegenerative diseases.
Key measurements being assessed include:
- Uptake values: How much [18F]MC225 accumulates in different brain regions, which reflects P-gp activity (higher uptake may indicate lower P-gp activity, as less tracer is being pumped out)
- Influx values: The rate at which [18F]MC225 enters brain tissue from the bloodstream
- Regional patterns: Differences in tracer distribution across various brain areas, which may correlate with disease-specific patterns
- Comparison between groups: Differences in measurements between patients with different conditions or treatment responses
These measurements will help researchers understand whether P-glycoprotein function is altered in treatment-resistant depression and neurodegenerative diseases, and whether these alterations follow specific patterns that could be clinically meaningful.
The data collected from these Phase 2 trials will be important for determining whether [18F]MC225 PET imaging can serve as a useful tool for understanding disease mechanisms, predicting treatment responses, or monitoring disease progression in these conditions.